Dr. Bauml Discusses the FLAURA Study in NSCLC

Joshua Bauml, MD
Published: Monday, Sep 18, 2017



Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the FLAURA trial in patients with EGFR-mutant non–small cell lung cancer (NSCLC).

FLAURA is a randomized phase III study of frontline osimertinib (Tagrisso) compared with either erlotinib (Tarceva) or gefitinib (Iressa).

Results showed an improvement in progression-free survival, and a trend was observed toward overall survival with osimertinib—though it is not yet statistically significant.
 
SELECTED
LANGUAGE


Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the FLAURA trial in patients with EGFR-mutant non–small cell lung cancer (NSCLC).

FLAURA is a randomized phase III study of frontline osimertinib (Tagrisso) compared with either erlotinib (Tarceva) or gefitinib (Iressa).

Results showed an improvement in progression-free survival, and a trend was observed toward overall survival with osimertinib—though it is not yet statistically significant.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How to Use Liquid Biopsies Throughout the Lung Cancer Treatment Continuum OnlineJan 31, 20191.5
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x